{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:39:54Z","timestamp":1788946794583,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI15C-1653"],"award-info":[{"award-number":["HI15C-1653"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002471","name":"Dongguk University","doi-asserted-by":"publisher","award":["Dongguk University Research Fund of 2019"],"award-info":[{"award-number":["Dongguk University Research Fund of 2019"]}],"id":[{"id":"10.13039\/501100002471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1068201"],"award-info":[{"award-number":["2020R1F1A1068201"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Moxifloxacin hydrochloride (MXF) is widely used for the prevention of bacterial endophthalmitis after intraocular surgeries. However, the safety issue of intracameral injection of MXF for human corneal endothelial cells (HCECs) is still debatable. In this study, we investigated concentration-dependent cytotoxicity (0.05\u20131\u00a0mg\/ml) of MXF for immortalized HCECs (B4G12 cell) and the underlying mechanism. Reactive oxygen generation (ROS) and cell viability after MXF exposure was measured. Flow cytometric analysis and TUNEL assay was used to detect apoptotic HCECs after MXF exposure. Ultrastructure of damaged HCECs by MXF was imaged by transmission electron microscope. Western blot analysis and caspase 2, 3 and 8 analysis were used to reveal the underlying mechanism of MXF induced damage in HCECs. We found that MXF induced dose-dependent cytotoxicity in HCECs. MXF exposure increased ROS generation and induced autophagy in HCECs. Increased LDH release represented the cellular membrane damage by MXF. In addition, caspases activation, Bax\/Bcl-xL-dependent apoptosis pathway and apoptosis inducing factor nuclear translocation were all involved in MXF induced HCECs\u2019 damage, especially after exposure to high dose of MXF (0.5 and 1.0\u00a0mg\/ml). These findings suggest that MXF toxicity on HCECs should be thoroughly considered by ophthalmologists when intracameral injection of MXF is planned.<\/jats:p>","DOI":"10.1038\/s41598-021-85834-x","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Joo-Hee","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Chuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choul Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85834_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1185\/030079906X132668","volume":"22","author":"KE Donaldson","year":"2006","unstructured":"Donaldson, K. E., Marangon, F. B., Schatz, L., Venkatraman, A. S. & Alfonso, E. C. The effect of moxifloxacin on the normal human cornea. Curr. Med. Res. Opin. 22, 2073\u20132080. https:\/\/doi.org\/10.1185\/030079906X132668 (2006).","journal-title":"Curr. Med. Res. Opin."},{"key":"85834_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcrs.2006.09.019","volume":"33","author":"CR Espiritu","year":"2007","unstructured":"Espiritu, C. R., Caparas, V. L. & Bolinao, J. G. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J. Cataract. Refract. Surg. 33, 63\u201368. https:\/\/doi.org\/10.1016\/j.jcrs.2006.09.019 (2007).","journal-title":"J. Cataract. Refract. Surg."},{"key":"85834_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jcrs.2008.05.034","volume":"34","author":"SS Lane","year":"2008","unstructured":"Lane, S. S., Osher, R. H., Masket, S. & Belani, S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J. Cataract. Refract. Surg. 34, 1451\u20131459. https:\/\/doi.org\/10.1016\/j.jcrs.2008.05.034 (2008).","journal-title":"J. Cataract. Refract. Surg."},{"key":"85834_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.10.044","author":"MV Melega","year":"2019","unstructured":"Melega, M. V. et al. Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: randomized controlled clinical trial. J. Cataract. Refract. Surg. https:\/\/doi.org\/10.1016\/j.jcrs.2018.10.044 (2019).","journal-title":"J. Cataract. Refract. Surg."},{"key":"85834_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/ICO.0b013e318191447b","volume":"28","author":"M Kernt","year":"2009","unstructured":"Kernt, M. et al. Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 28, 553\u2013561. https:\/\/doi.org\/10.1097\/ICO.0b013e318191447b (2009).","journal-title":"Cornea"},{"key":"85834_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10384-010-0838-5","volume":"54","author":"S Kobayakawa","year":"2010","unstructured":"Kobayakawa, S., Hiratsuka, Y., Watabe, Y., Murakami, A. & Tochikubo, T. Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model. Jpn. J. Ophthalmol. 54, 481\u2013485. https:\/\/doi.org\/10.1007\/s10384-010-0838-5 (2010).","journal-title":"Jpn. J. Ophthalmol."},{"key":"85834_CR7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/ICO.0000000000000967","volume":"35","author":"LC Carrijo-Carvalho","year":"2016","unstructured":"Carrijo-Carvalho, L. C., Teixeira, A., de Freitas, D. & Carvalho, F. R. Toxicity of intracameral injection of fourth-generation fluoroquinolones on the corneal endothelium. Cornea 35, 1631\u20131637. https:\/\/doi.org\/10.1097\/ICO.0000000000000967 (2016).","journal-title":"Cornea"},{"key":"85834_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4265\/bio.15.97","volume":"15","author":"M Ayaki","year":"2010","unstructured":"Ayaki, M. et al. Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. Biocontrol Sci. 15, 97\u2013102 (2010).","journal-title":"Biocontrol Sci."},{"key":"85834_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/jop.2014.0029","volume":"30","author":"K Matsuura","year":"2014","unstructured":"Matsuura, K. et al. Safety of intracameral injection of moxifloxacin using total replacement technique (bag and chamber flushing). J. Ocular Pharmacol. Therap. 30, 771\u2013776. https:\/\/doi.org\/10.1089\/jop.2014.0029 (2014).","journal-title":"J. Ocular Pharmacol. Therap."},{"key":"85834_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3109\/02713683.2012.763101","volume":"38","author":"L Asena","year":"2013","unstructured":"Asena, L. et al. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model. Curr. Eye Res. 38, 472\u2013479. https:\/\/doi.org\/10.3109\/02713683.2012.763101 (2013).","journal-title":"Curr. Eye Res."},{"key":"85834_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1350-9462(02)00065-4","volume":"22","author":"NC Joyce","year":"2003","unstructured":"Joyce, N. C. Proliferative capacity of the corneal endothelium. Prog. Retin. Eye Res. 22, 359\u2013389 (2003).","journal-title":"Prog. Retin. Eye Res."},{"key":"85834_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/15569527.2014.918138","volume":"34","author":"A Akal","year":"2015","unstructured":"Akal, A. et al. Does moxifloxacin alter oxidant status in the cornea? An experimental study. Cutan. Ocul. Toxicol. 34, 139\u2013143. https:\/\/doi.org\/10.3109\/15569527.2014.918138 (2015).","journal-title":"Cutan. Ocul. Toxicol."},{"key":"85834_CR13","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jcrs.2014.08.027","volume":"40","author":"T Haruki","year":"2014","unstructured":"Haruki, T. et al. Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro. J. Cataract Refract. Surg. 40, 1872\u20131878. https:\/\/doi.org\/10.1016\/j.jcrs.2014.08.027 (2014).","journal-title":"J. Cataract Refract. Surg."},{"key":"85834_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ebiom.2018.03.016","volume":"30","author":"D Bano","year":"2018","unstructured":"Bano, D. & Prehn, J. H. M. Apoptosis-inducing factor (AIF) in physiology and disease: the tale of a repented natural born killer. EBioMedicine 30, 29\u201337. https:\/\/doi.org\/10.1016\/j.ebiom.2018.03.016 (2018).","journal-title":"EBioMedicine"},{"key":"85834_CR15","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.bbamcr.2016.09.012","volume":"2977\u20132992","author":"M Redza-Dutordoir","year":"1863","unstructured":"Redza-Dutordoir, M. & Averill-Bates, D. A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochem. Biophys. Acta 2977\u20132992, 2016. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.09.012 (1863).","journal-title":"Biochem. Biophys. Acta"},{"key":"85834_CR16","first-page":"1416","volume":"25","author":"JS Minkowski","year":"1984","unstructured":"Minkowski, J. S. et al. Corneal endothelial function and structure following cryo-injury in the rabbit. Invest. Ophthalmol. Vis. Sci. 25, 1416\u20131425 (1984).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"85834_CR17","first-page":"1199","volume":"27","author":"SJ Tuft","year":"1986","unstructured":"Tuft, S. J., Williams, K. A. & Coster, D. J. Endothelial repair in the rat cornea. Invest. Ophthalmol. Vis. Sci. 27, 1199\u20131204 (1986).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"85834_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","volume":"4","author":"Z Jin","year":"2005","unstructured":"Jin, Z. & El-Deiry, W. S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4, 139\u2013163. https:\/\/doi.org\/10.4161\/cbt.4.2.1508 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"85834_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051259","author":"V Vigneswara","year":"2020","unstructured":"Vigneswara, V. & Ahmed, Z. The role of caspase-2 in regulating cell fate. Cells https:\/\/doi.org\/10.3390\/cells9051259 (2020).","journal-title":"Cells"},{"key":"85834_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/jat.1081","volume":"25","author":"YK Kim","year":"2005","unstructured":"Kim, Y. K. et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol. 25, 374\u2013382. https:\/\/doi.org\/10.1002\/jat.1081 (2005).","journal-title":"J. Appl. Toxicol."},{"key":"85834_CR21","doi-asserted-by":"publisher","first-page":"H1956","DOI":"10.1152\/ajpheart.00407.2008","volume":"295","author":"J Liu","year":"2008","unstructured":"Liu, J., Mao, W., Ding, B. & Liang, C. S. ERKs\/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 295, H1956-1965. https:\/\/doi.org\/10.1152\/ajpheart.00407.2008 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"85834_CR22","doi-asserted-by":"publisher","first-page":"12710","DOI":"10.1074\/jbc.M111598200","volume":"277","author":"D Tang","year":"2002","unstructured":"Tang, D. et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710\u201312717. https:\/\/doi.org\/10.1074\/jbc.M111598200 (2002).","journal-title":"J. Biol. Chem."},{"key":"85834_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.onc.1204062","volume":"20","author":"SS Bacus","year":"2001","unstructured":"Bacus, S. S. et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20, 147\u2013155. https:\/\/doi.org\/10.1038\/sj.onc.1204062 (2001).","journal-title":"Oncogene"},{"key":"85834_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00210-019-01711-5","volume":"393","author":"TJ Fan","year":"2020","unstructured":"Fan, T. J., Wu, S. X. & Jiang, G. J. Apoptotic effects of norfloxacin on corneal endothelial cells. Naunyn Schmiedebergs Arch. Pharmacol. 393, 77\u201388. https:\/\/doi.org\/10.1007\/s00210-019-01711-5 (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"85834_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/OPTH.S1666","volume":"2","author":"D Miller","year":"2008","unstructured":"Miller, D. Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections. Clin. Ophthalmol. 2, 77\u201391 (2008).","journal-title":"Clin. Ophthalmol."},{"key":"85834_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s00347-009-2027-9","volume":"107","author":"M Kernt","year":"2010","unstructured":"Kernt, M. et al. Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 107, 720\u2013727. https:\/\/doi.org\/10.1007\/s00347-009-2027-9 (2010).","journal-title":"Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft"},{"key":"85834_CR27","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.jcrs.2016.10.017","volume":"42","author":"SA Arshinoff","year":"2016","unstructured":"Arshinoff, S. A. & Modabber, M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J. Cataract. Refract. Surg. 42, 1730\u20131741. https:\/\/doi.org\/10.1016\/j.jcrs.2016.10.017 (2016).","journal-title":"J. Cataract. Refract. Surg."},{"key":"85834_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5935\/0004-2749.20180022","volume":"81","author":"NP Lucena","year":"2018","unstructured":"Lucena, N. P. et al. Intracameral moxifloxacin after cataract surgery: a prospective study. Arq. Bras. Oftalmol. 81, 92\u201394. https:\/\/doi.org\/10.5935\/0004-2749.20180022 (2018).","journal-title":"Arq. Bras. Oftalmol."},{"key":"85834_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ophtha.2017.01.026","volume":"124","author":"A Haripriya","year":"2017","unstructured":"Haripriya, A., Chang, D. F. & Ravindran, R. D. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology 124, 768\u2013775. https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.026 (2017).","journal-title":"Ophthalmology"},{"key":"85834_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2015.09.037","volume":"123","author":"A Haripriya","year":"2016","unstructured":"Haripriya, A., Chang, D. F., Namburar, S., Smita, A. & Ravindran, R. D. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology 123, 302\u2013308. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.037 (2016).","journal-title":"Ophthalmology"},{"key":"85834_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-012-2098-1","volume":"251","author":"K Matsuura","year":"2013","unstructured":"Matsuura, K., Suto, C., Akura, J. & Inoue, Y. Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens. Graefe\u2019s Arch. Clin. Exp. Ophthalmol. 251, 81\u201387. https:\/\/doi.org\/10.1007\/s00417-012-2098-1 (2013).","journal-title":"Graefe's Arch. Clin. Exp. Ophthalmol."},{"key":"85834_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.exer.2011.08.014","volume":"95","author":"NC Joyce","year":"2012","unstructured":"Joyce, N. C. Proliferative capacity of corneal endothelial cells. Exp. Eye Res. 95, 16\u201323. https:\/\/doi.org\/10.1016\/j.exer.2011.08.014 (2012).","journal-title":"Exp. Eye Res."},{"key":"85834_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000113406","volume":"187","author":"M Valtink","year":"2008","unstructured":"Valtink, M., Gruschwitz, R., Funk, R. H. & Engelmann, K. Two clonal cell lines of immortalized human corneal endothelial cells show either differentiated or precursor cell characteristics. Cells Tissues Organs 187, 286\u2013294. https:\/\/doi.org\/10.1159\/000113406 (2008).","journal-title":"Cells Tissues Organs"},{"key":"85834_CR34","first-page":"1439","volume":"16","author":"F Sornelli","year":"2010","unstructured":"Sornelli, F., Lambiase, A., Mantelli, F. & Aloe, L. NGF and NGF-receptor expression of cultured immortalized human corneal endothelial cells. Mol. Vis. 16, 1439\u20131447 (2010).","journal-title":"Mol. Vis."},{"key":"85834_CR35","doi-asserted-by":"publisher","first-page":"15014","DOI":"10.1038\/mtm.2015.14","volume":"2","author":"YJ Hsueh","year":"2015","unstructured":"Hsueh, Y. J. et al. Lysophosphatidic acid induces YAP-promoted proliferation of human corneal endothelial cells via PI3K and ROCK pathways. Mol. Ther. Methods Clin. Dev. 2, 15014. https:\/\/doi.org\/10.1038\/mtm.2015.14 (2015).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"85834_CR36","doi-asserted-by":"publisher","first-page":"e50993","DOI":"10.1371\/journal.pone.0050993","volume":"7","author":"HJ Levis","year":"2012","unstructured":"Levis, H. J. et al. Plastic compressed collagen as a novel carrier for expanded human corneal endothelial cells for transplantation. PLoS ONE 7, e50993. https:\/\/doi.org\/10.1371\/journal.pone.0050993 (2012).","journal-title":"PLoS ONE"},{"key":"85834_CR37","doi-asserted-by":"publisher","first-page":"14566","DOI":"10.1038\/s41598-017-15247-2","volume":"7","author":"JY Kim","year":"2017","unstructured":"Kim, J. Y. et al. Safety of nonporous silica nanoparticles in human corneal endothelial cells. Sci. Rep. 7, 14566. https:\/\/doi.org\/10.1038\/s41598-017-15247-2 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85834-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:21:56Z","timestamp":1670044916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85834"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85834-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"20 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6250"}}